Fostemsavir
This antiretroviral prodrug is converted to temsavir, which blocks HIV entry into human cells by binding directly to the viral gp120 protein and preventing it from attaching to the CD4 receptor. It is used in heavily treatment-experienced adults with multidrug-resistant HIV.
Peso molecular
583,5000 g/mol
LogP
-0,10
TPSA
182,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COc1cnc(-n2cnc(C)n2)c2c1c(C(=O)C(=O)N1CCN(C(=O)c3ccccc3)CC1)cn2COP(=O)(O)O
InChI
InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)
Molecular Formula
C25H26N7O8P
HBD / HBA
2 / 11
Enlaces Rotables
8
Átomos Pesados
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This antiretroviral prodrug is converted to temsavir, which blocks HIV entry into human cells by binding directly to the viral gp120 protein and preventing it from attaching to the CD4 receptor. It is used in heavily treatment-experienced adults with multidrug-resistant HIV.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Fostemsavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301594. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11319217. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fostemsavir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fostemsavir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fostemsavir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fostemsavir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fostemsavir"></drugfyi-drug>